Beam Therapeutics shares surged more than 12% in premarket trading.
Gene editing is the next phase of genetic medicine, and another big step was just announced. Monday morning, Pfizer (ticker: PFE) unveiled a $1.3 billion partnership with Beam Therapeutics (BEAM) to develop three treatments for genetic disease in the next four years. They’ll use Beam’s leading-edge technology that makes precise corrections to typographical errors in our genes—a technology called “base editing”.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments